Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04433585




Registration number
NCT04433585
Ethics application status
Date submitted
15/06/2020
Date registered
16/06/2020
Date last updated
23/04/2024

Titles & IDs
Public title
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Secondary ID [1] 0 0
J1P-MC-KFAJ
Secondary ID [2] 0 0
17422
Universal Trial Number (UTN)
Trial acronym
ISLAND-SLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LY3471851
Treatment: Drugs - Placebo

Experimental: LY3471851 High Dose - LY3471851 administered subcutaneously (SC).

Experimental: LY3471851 Mid Dose - LY3471851 administered SC.

Experimental: LY3471851 Low Dose - LY3471851 administered SC

Placebo Comparator: Placebo - Placebo administered SC.


Treatment: Drugs: LY3471851
Administered SC

Treatment: Drugs: Placebo
Administered SC
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved a =4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Percentage of Participants Who Achieved British Isles Lupus Assessment Group (BILAG) Based Composite Lupus Assessment (BICLA) Response at Week 24.
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants Who Achieved Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 24
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 24
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
Pharmacokinetics (PK): Trough Concentrations (Ctrough) of LY3471851
Timepoint [4] 0 0
Week 24

Eligibility
Key inclusion criteria
- Have a clinical diagnosis of SLE at least 24 weeks prior to screening.

- Have documentation of having met at least 4 of 11 Revised Criteria for Classification
of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American
College of Rheumatology (ACR) criteria for classification of SLE prior to
randomization.

- Have a positive antinuclear antibody (ANA) (titer =1:80) and/or a positive
anti-double-stranded deoxyribonucleic acid (dsDNA), and/or a positive anti-Smith
(anti-Sm) as assessed by a central laboratory during screening.

- Have a total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
score =6 during screening.

- Have a clinical SLEDAI-2K score =4 at randomization.

- Have active arthritis and/or active rash.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have severe active lupus nephritis.

- Have active central nervous system (CNS) lupus.

- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute an unacceptable risk when taking investigational product or interfere with
the interpretation of data.

- Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/08/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/02/2023
Sample size
Target
Accrual to date
Final
291
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Emeritus Research - Camberwell
Recruitment postcode(s) [1] 0 0
3124 - Camberwell
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oklahoma
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Ciudad Autónoma De Buenos Aire
Country [14] 0 0
Argentina
State/province [14] 0 0
Tucumán
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autónoma de Buenos Aire
Country [16] 0 0
Argentina
State/province [16] 0 0
Córdoba
Country [17] 0 0
Argentina
State/province [17] 0 0
San Juan
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Czechia
State/province [19] 0 0
Ostrava Mesto
Country [20] 0 0
Czechia
State/province [20] 0 0
Praha, Hlavní Mešto
Country [21] 0 0
Germany
State/province [21] 0 0
Baden-Württemberg
Country [22] 0 0
Germany
State/province [22] 0 0
Nordrhein-Westfalen
Country [23] 0 0
Germany
State/province [23] 0 0
North Rhine-Westphalia
Country [24] 0 0
Germany
State/province [24] 0 0
Schleswig-Holstein
Country [25] 0 0
Germany
State/province [25] 0 0
Kiel
Country [26] 0 0
Germany
State/province [26] 0 0
Köln
Country [27] 0 0
Hungary
State/province [27] 0 0
Békés
Country [28] 0 0
Hungary
State/province [28] 0 0
Budapest
Country [29] 0 0
Hungary
State/province [29] 0 0
Debrecen
Country [30] 0 0
India
State/province [30] 0 0
Andhra Pradesh
Country [31] 0 0
India
State/province [31] 0 0
Delhi
Country [32] 0 0
India
State/province [32] 0 0
Gujarat
Country [33] 0 0
India
State/province [33] 0 0
Karnataka
Country [34] 0 0
India
State/province [34] 0 0
Maharashtra
Country [35] 0 0
Israel
State/province [35] 0 0
HaMerkaz
Country [36] 0 0
Israel
State/province [36] 0 0
Haifa
Country [37] 0 0
Israel
State/province [37] 0 0
Kfar Saba
Country [38] 0 0
Israel
State/province [38] 0 0
Tel Aviv
Country [39] 0 0
Japan
State/province [39] 0 0
Aichi
Country [40] 0 0
Japan
State/province [40] 0 0
Fukuoka
Country [41] 0 0
Japan
State/province [41] 0 0
Hokkaido
Country [42] 0 0
Japan
State/province [42] 0 0
Miyagi
Country [43] 0 0
Japan
State/province [43] 0 0
Nagano
Country [44] 0 0
Japan
State/province [44] 0 0
Nagasaki
Country [45] 0 0
Japan
State/province [45] 0 0
Chiba
Country [46] 0 0
Japan
State/province [46] 0 0
Okayama
Country [47] 0 0
Japan
State/province [47] 0 0
Osaka
Country [48] 0 0
Japan
State/province [48] 0 0
Tokyo
Country [49] 0 0
Korea, Republic of
State/province [49] 0 0
Gyeonggi-do
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Korea
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Seoul, Korea
Country [52] 0 0
Mexico
State/province [52] 0 0
Baja California
Country [53] 0 0
Mexico
State/province [53] 0 0
Coahuila
Country [54] 0 0
Mexico
State/province [54] 0 0
Distrito Federal
Country [55] 0 0
Mexico
State/province [55] 0 0
Jalisco
Country [56] 0 0
Poland
State/province [56] 0 0
Mazowieckie
Country [57] 0 0
Poland
State/province [57] 0 0
Podlaskie
Country [58] 0 0
Poland
State/province [58] 0 0
Bydgoszcz
Country [59] 0 0
Poland
State/province [59] 0 0
Slaskie
Country [60] 0 0
Puerto Rico
State/province [60] 0 0
Caguas
Country [61] 0 0
Puerto Rico
State/province [61] 0 0
San Juan
Country [62] 0 0
Romania
State/province [62] 0 0
Bra?ov
Country [63] 0 0
Romania
State/province [63] 0 0
Bucuresti
Country [64] 0 0
Romania
State/province [64] 0 0
Galati
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Kareliya, Respublika
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Moskva
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Moscow
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Ryazan
Country [69] 0 0
Spain
State/province [69] 0 0
Barcelona
Country [70] 0 0
Spain
State/province [70] 0 0
Sevilla
Country [71] 0 0
Taiwan
State/province [71] 0 0
Kaohsiung City
Country [72] 0 0
Taiwan
State/province [72] 0 0
Taichung City
Country [73] 0 0
Taiwan
State/province [73] 0 0
Taichung
Country [74] 0 0
Taiwan
State/province [74] 0 0
Taipei City
Country [75] 0 0
Ukraine
State/province [75] 0 0
Kharkiv
Country [76] 0 0
Ukraine
State/province [76] 0 0
Kyiv
Country [77] 0 0
Ukraine
State/province [77] 0 0
Odesa
Country [78] 0 0
Ukraine
State/province [78] 0 0
Vinnytsya
Country [79] 0 0
Ukraine
State/province [79] 0 0
Zaporizhzhia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Nektar Therapeutics
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and
effective in adults with systemic lupus erythematosus (SLE).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04433585
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Nektar Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04433585